Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Might Seek "Intermediate" Action Authority To Enforce Trial Compliance

This article was originally published in The Gray Sheet

Executive Summary

FDA is considering whether to ask Congress for the authority to bring "intermediate" enforcement actions against parties violating clinical trial regs, FDA Office of Regulatory Affairs Director of Enforcement Daniel Michels told the Government Reform/Criminal Justice, Drug Policy and Human Resources Subcommittee.

You may also be interested in...



FDA Civil Monetary Penalties For Human Subject Protection Sought By HHS

HHS plans to submit a legislative proposal to Congress by year-end that would authorize FDA to levy civil monetary penalties for infractions of human research subject protections rules, the Clinton administration announced May 23.

US FDA Pharmaceutical Quality Office Lauds Continuous Manufacturing Approvals

The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.

UsernamePublicRestriction

Register

MT013332

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel